| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| KRYSKrystal Biotech, Inc. | 8.18B | 282.01 | 94.00 | 473.02% | 53.3% | 17.48% | 1.46% | 0.01 |
| BMRNBioMarin Pharmaceutical Inc. | 10.58B | 55.07 | 24.92 | 17.97% | 16.82% | 8.59% | 4.49% | 0.11 |
| SRPTSarepta Therapeutics, Inc. | 2.23B | 21.31 | 9.11 | 52.97% | -11.25% | -20.57% | 0.88 | |
| RAREUltragenyx Pharmaceutical Inc. | 2.27B | 23.50 | -3.74 | 29.01% | -91.95% | -35.88% | 0.15 | |
| DYNDyne Therapeutics, Inc. | 2.7B | 16.42 | -4.87 | -61.26% | 0.04 | |||
| TVTXTravere Therapeutics, Inc. | 2.54B | 28.40 | -6.96 | 60.55% | -20.32% | -120.36% | 6.80 | |
| BEAMBeam Therapeutics Inc. | 3.25B | 32.05 | -7.00 | -83.18% | -7.44% | -42.92% | 0.22 | |
| SLNOSoleno Therapeutics, Inc. | 2.25B | 41.95 | -9.58 | -79.5% | -15.85% | 0.22 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 40.56M | 8.25M | 69.72M | 77.65M | 9.3M | 221.9M |
| Revenue Growth % | - | - | - | -0.8% | 7.45% | 0.11% | -0.88% | 22.85% |
| Cost of Goods Sold | 260K | 0 | 2.5M | 0 | 3.11M | 3.43M | 2.45M | 3.88M |
| COGS % of Revenue | - | - | 0.06% | - | 0.04% | 0.04% | 0.26% | 0.02% |
| Gross Profit | -260K | 0 | 38.06M | 8.25M | 66.6M | 74.21M | 6.86M | 218.02M |
| Gross Margin % | - | - | 0.94% | 1% | 0.96% | 0.96% | 0.74% | 0.98% |
| Gross Profit Growth % | - | 1% | - | -0.78% | 7.07% | 0.11% | -0.91% | 30.8% |
| Operating Expenses | 43.86M | 183.66M | 304.3M | 482.73M | 643.23M | 586.42M | 614.23M | 811M |
| OpEx % of Revenue | - | - | 7.5% | 58.52% | 9.23% | 7.55% | 66.02% | 3.65% |
| Selling, General & Admin | 13.3M | 43.59M | 94.35M | 145.68M | 192.21M | 143.19M | 150.59M | 288.93M |
| SG&A % of Revenue | - | - | 2.33% | 17.66% | 2.76% | 1.84% | 16.19% | 1.3% |
| Research & Development | 30.56M | 140.07M | 209.95M | 337.05M | 451.02M | 399.46M | 455.71M | 506.46M |
| R&D % of Revenue | - | - | 5.18% | 40.86% | 6.47% | 5.14% | 48.99% | 2.28% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 43.77M | 7.93M | 15.61M |
| Operating Income | -43.86M | -183.66M | -266.24M | -474.48M | -576.63M | -512.2M | -607.37M | -592.97M |
| Operating Margin % | - | - | -6.56% | -57.52% | -8.27% | -6.6% | -65.29% | -2.67% |
| Operating Income Growth % | - | -3.19% | -0.45% | -0.78% | -0.22% | 0.11% | -0.19% | 0.02% |
| EBITDA | -43.6M | -183.41M | -265.38M | -473.03M | -570.79M | -505.43M | -600.88M | -586.9M |
| EBITDA Margin % | - | - | -6.54% | -57.34% | -8.19% | -6.51% | -64.59% | -2.64% |
| EBITDA Growth % | - | -3.21% | -0.45% | -0.78% | -0.21% | 0.11% | -0.19% | 0.02% |
| D&A (Non-Cash Add-back) | 260K | 245K | 859K | 1.46M | 5.84M | 6.77M | 6.49M | 6.08M |
| EBIT | -43.82M | -183.66M | -279.82M | -468.83M | -539.68M | -404.21M | -571.96M | -442.9M |
| Net Interest Income | 26K | -543K | 150K | -32.64M | -45.65M | -72.9M | -63.25M | -82.04M |
| Interest Income | 39K | 2M | 8.91M | 4.01M | 1.13M | 7.54M | 18.04M | 17.25M |
| Interest Expense | 13K | 2.55M | 8.77M | 36.66M | 46.78M | 80.44M | 81.29M | 99.29M |
| Other Income/Expense | 26K | 14.21M | -22.34M | -31.01M | -9.82M | 27.55M | -45.88M | 50.78M |
| Pretax Income | -43.83M | -169.45M | -288.58M | -505.49M | -586.45M | -484.65M | -653.25M | -542.19M |
| Pretax Margin % | - | - | -7.12% | -61.28% | -8.41% | -6.24% | -70.22% | -2.44% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.15M |
| Effective Tax Rate % | 0.7% | 0.77% | 0.9% | 0.89% | 0.96% | 0.99% | 0.98% | 0.99% |
| Net Income | -30.57M | -130.75M | -260.44M | -448.72M | -562.54M | -481.18M | -643.2M | -535.76M |
| Net Margin % | - | - | -6.42% | -54.4% | -8.07% | -6.2% | -69.14% | -2.41% |
| Net Income Growth % | - | -3.28% | -0.99% | -0.72% | -0.25% | 0.14% | -0.34% | 0.17% |
| Net Income (Continuing) | -43.83M | -169.45M | -288.58M | -505.49M | -586.45M | -484.65M | -653.25M | -543.35M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 3.33M | 62.48M | 67.52M | 49.98M | 4.83M | 9.69M | 11.72M | 10.29M |
| EPS (Diluted) | -0.33 | -1.42 | -2.48 | -4.10 | -4.43 | -3.35 | -3.95 | -2.88 |
| EPS Growth % | - | -3.3% | -0.75% | -0.65% | -0.08% | 0.24% | -0.18% | 0.27% |
| EPS (Basic) | -0.33 | -1.42 | -2.48 | -4.10 | -4.43 | -3.35 | -3.95 | -2.88 |
| Diluted Shares Outstanding | 92.33M | 92.33M | 105.1M | 118M | 144.36M | 147.47M | 162.79M | 186.08M |
| Basic Shares Outstanding | 92.33M | 92.33M | 105.1M | 118M | 144.36M | 147.47M | 162.79M | 186.08M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 97.13M | 445.22M | 568.62M | 642.82M | 888.86M | 548.85M | 477.59M | 720.69M |
| Cash & Short-Term Investments | 92M | 436.09M | 545.99M | 607.09M | 836.66M | 471.92M | 434.88M | 681.1M |
| Cash Only | 92M | 436.09M | 363.77M | 356.08M | 393.77M | 376.69M | 375.94M | 681.1M |
| Short-Term Investments | 0 | 0 | 182.22M | 251.01M | 442.89M | 95.23M | 58.95M | 0 |
| Accounts Receivable | 0 | 0 | 2.85M | 0 | 19.75M | 17.08M | 1.75M | 4.72M |
| Days Sales Outstanding | - | - | 25.6 | - | 103.4 | 80.28 | 68.7 | 7.77 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 889K | 0 | 0 | 139K | 177K | 37.93M | 27.65M | 3.83M |
| Total Non-Current Assets | 913K | 19.72M | 63.06M | 60.76M | 123.93M | 74.18M | 68.79M | 198.65M |
| Property, Plant & Equipment | 440K | 1.57M | 5.63M | 36.83M | 45.97M | 25.25M | 19.84M | 12.78M |
| Fixed Asset Turnover | - | - | 7.21x | 0.22x | 1.52x | 3.08x | 0.47x | 17.37x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 44.93M | 28.71M | 26.32M | 23.93M |
| Long-Term Investments | 381K | 17.05M | 31.14M | 0 | 0 | 0 | 0 | 143.75M |
| Other Non-Current Assets | 92K | 1.09M | 26.29M | 23.93M | 33.03M | 20.22M | 22.63M | 18.2M |
| Total Assets | 98.04M | 464.94M | 631.68M | 703.59M | 1.01B | 623.04M | 546.38M | 919.34M |
| Asset Turnover | - | - | 0.06x | 0.01x | 0.07x | 0.12x | 0.02x | 0.24x |
| Asset Growth % | - | 3.74% | 0.36% | 0.11% | 0.44% | -0.38% | -0.12% | 0.68% |
| Total Current Liabilities | 8.55M | 32.58M | 60.38M | 95.65M | 135.07M | 121.43M | 143.84M | 154.4M |
| Accounts Payable | 1.89M | 13.51M | 8.85M | 8.95M | 11.88M | 11.56M | 10.65M | 9.62M |
| Days Payables Outstanding | 2.65K | - | 1.29K | - | 1.39K | 1.23K | 1.59K | 905.25 |
| Short-Term Debt | 0 | 0 | 0 | 1.46M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 1000K | 1000K | 0 |
| Other Current Liabilities | 997K | 4.01M | 25.39M | 9.55M | 37.04M | 31.26M | 65.59M | 16.2M |
| Current Ratio | 11.36x | 13.67x | 9.42x | 6.72x | 6.58x | 4.52x | 3.32x | 4.67x |
| Quick Ratio | 11.36x | 13.67x | 9.42x | 6.72x | 6.58x | 4.52x | 3.32x | 4.67x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 144.18M | 533.87M | 95.32M | 500.05M | 1.74B | 1.75B | 1.75B | 2.22B |
| Long-Term Debt | 143.87M | 54.51M | 91.79M | 475.86M | 1.7B | 1.71B | 1.73B | 1.72B |
| Capital Lease Obligations | 0 | 0 | 0 | 14.68M | 17.43M | 12.27M | 8.98M | 4.7M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 312K | 479.36M | 3.53M | 9.52M | 22.07M | 26.64M | 9.36M | 496.47M |
| Total Liabilities | 152.73M | 566.44M | 155.7M | 595.7M | 1.88B | 1.87B | 1.89B | 2.38B |
| Total Debt | 143.87M | 54.51M | 91.79M | 495.79M | 1.73B | 1.72B | 1.74B | 1.73B |
| Net Debt | 51.87M | -381.58M | -271.98M | 139.71M | 1.33B | 1.35B | 1.36B | 1.05B |
| Debt / Equity | - | - | 0.19x | 4.60x | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | -3373.69x | -72.11x | -30.38x | -12.94x | -12.33x | -6.37x | -7.47x | -5.97x |
| Total Equity | -54.69M | -101.5M | 475.98M | 107.89M | -865.58M | -1.24B | -1.34B | -1.46B |
| Equity Growth % | - | -0.86% | 5.69% | -0.77% | -9.02% | -0.44% | -0.08% | -0.09% |
| Book Value per Share | -0.59 | -1.10 | 4.53 | 0.91 | -6.00 | -8.44 | -8.25 | -7.83 |
| Total Shareholders' Equity | -58.02M | -163.99M | 408.45M | 57.91M | -870.41M | -1.25B | -1.35B | -1.47B |
| Common Stock | 3.41M | 6.59M | 124K | 125K | 154K | 157K | 181K | 196K |
| Retained Earnings | -61.43M | -170.58M | -440.03M | -888.75M | -1.44B | -1.92B | -2.56B | -3.1B |
| Treasury Stock | 0 | 0 | 0 | -75M | -275M | -275M | -275M | -275M |
| Accumulated OCI | -27K | -231K | 254K | 192K | -132K | -328K | 31K | 8K |
| Minority Interest | 3.33M | 62.48M | 67.52M | 49.98M | 4.83M | 9.69M | 11.72M | 10.29M |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -40.49M | -136.64M | -253.59M | -399.71M | -497.93M | -419.49M | -527.72M | -520.73M |
| Operating CF Margin % | - | - | -6.25% | -48.46% | -7.14% | -5.4% | -56.73% | -2.35% |
| Operating CF Growth % | - | -2.37% | -0.86% | -0.58% | -0.25% | 0.16% | -0.26% | 0.01% |
| Net Income | -43.83M | -169.45M | -288.58M | -505.49M | -586.45M | -484.65M | -643.2M | -543.35M |
| Depreciation & Amortization | 260K | 245K | 859K | 3.09M | 5.84M | 6.77M | 6.49M | 6.08M |
| Stock-Based Compensation | 1.84M | 6.07M | 21.37M | 58.46M | 99.5M | 91.56M | 0 | 95.8M |
| Deferred Taxes | -260K | -14.89M | -859K | -1.87M | -30.93M | 0 | 0 | 0 |
| Other Non-Cash Items | 260K | 18.89M | 24.54M | 31.16M | 18.5M | -61.25M | 103.93M | -111.3M |
| Working Capital Changes | 1.24M | 22.49M | -10.91M | 14.93M | -4.4M | 28.08M | 5.06M | 32.04M |
| Change in Receivables | 0 | 0 | -2.85M | 2.85M | -19.75M | 15.17M | 15.33M | -2.97M |
| Change in Inventory | 0 | 0 | 2.85M | -2.85M | 19.75M | 0 | 0 | 0 |
| Change in Payables | 1.58M | 16.7M | -4.66M | -735K | 2.83M | -349K | 2.78M | 1.51M |
| Cash from Investing | -464K | -21.04M | -217.25M | -52.99M | -200.83M | 453.15M | 54.03M | 60.78M |
| Capital Expenditures | -464K | -18.18M | -5.14M | -7.52M | -48.25M | -4.82M | -1.31M | -933K |
| CapEx % of Revenue | - | - | 0.13% | 0.91% | 0.69% | 0.06% | 0.14% | 0% |
| Acquisitions | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -2.86M | 784K | -21.09M | 48.65M | 118.5M | -503K | -7.97M |
| Cash from Financing | 112.98M | 501.55M | 398.79M | 447.19M | 736.45M | -13.13M | 451.54M | 748.46M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - |
| Dividends Paid | -1.15M | 0 | -997K | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - |
| Other Financing | 1.83M | 14.64M | -4.38M | -27.1M | -138.49M | 4.06M | 8.61M | -35.34M |
| Net Change in Cash | - | - | - | - | - | - | - | - |
| Free Cash Flow | -40.95M | -154.82M | -258.73M | -407.23M | -546.18M | -425.81M | -529.03M | -521.66M |
| FCF Margin % | - | - | -6.38% | -49.37% | -7.83% | -5.48% | -56.87% | -2.35% |
| FCF Growth % | - | -2.78% | -0.67% | -0.57% | -0.34% | 0.22% | -0.24% | 0.01% |
| FCF per Share | -0.44 | -1.68 | -2.46 | -3.45 | -3.78 | -2.89 | -3.25 | -2.80 |
| FCF Conversion (FCF/Net Income) | 1.32x | 1.05x | 0.97x | 0.89x | 0.89x | 0.87x | 0.82x | 0.97x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 54.44M | 61.11M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -139.1% | -153.71% | - | - | - | - |
| Return on Invested Capital (ROIC) | - | - | - | -157.61% | -121.07% | -135.08% | -738.78% | - |
| Gross Margin | - | - | 93.84% | 100% | 95.53% | 95.58% | 73.71% | 98.25% |
| Net Margin | - | - | -642.1% | -5439.74% | -806.9% | -619.7% | -6913.92% | -241.44% |
| Debt / Equity | - | - | 0.19x | 4.60x | - | - | - | - |
| Interest Coverage | -3373.69x | -72.11x | -30.38x | -12.94x | -12.33x | -6.37x | -7.47x | -5.97x |
| FCF Conversion | 1.32x | 1.05x | 0.97x | 0.89x | 0.89x | 0.87x | 0.82x | 0.97x |
| Revenue Growth | - | - | - | -79.66% | 745.14% | 11.38% | -88.02% | 2285.27% |
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| License | 13.8M | 8M | 65.92M |
| License Growth | - | -42.03% | 724.04% |
| Product | - | - | 3.79M |
| Product Growth | - | - | - |
BridgeBio Pharma, Inc. (BBIO) reported $353.8M in revenue for fiscal year 2024.
BridgeBio Pharma, Inc. (BBIO) grew revenue by 2285.3% over the past year. This is strong growth.
BridgeBio Pharma, Inc. (BBIO) reported a net loss of $797.1M for fiscal year 2024.
BridgeBio Pharma, Inc. (BBIO) had negative free cash flow of $595.2M in fiscal year 2024, likely due to heavy capital investments.